# A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

Study · id `cardio:ct-nct07843485` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07843485](<https://clinicaltrials.gov/study/NCT07843485>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07843485

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07843485. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-09 (actual); primary completion 2028-10-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07843485, source copy `cardio:ctgov-nct07843485-2026-11-05`, retrieved 2026-11-18)
- Started: 2026-10-09 (actual) (ClinicalTrials.gov record NCT07843485, source copy `cardio:ctgov-nct07843485-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2028-10-20 (anticipated) (ClinicalTrials.gov record NCT07843485, source copy `cardio:ctgov-nct07843485-2026-11-05`, retrieved 2026-11-18)
- Completion: 2029-01-19 (anticipated) (ClinicalTrials.gov record NCT07843485, source copy `cardio:ctgov-nct07843485-2026-11-05`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07843485, source copy `cardio:ctgov-nct07843485-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07843485-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
- Acronym: ZUPREME-4
- Condition: Obesity or Overweight
- Condition: Type 2 Diabetes
- Intervention (Combination product): Petrelintide
- Intervention (Combination product): Placebo
- Lead sponsor: Hoffmann-La Roche
- Lead sponsor class: INDUSTRY
- Collaborator: Zealand Pharma
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

## Provenance

Content hash: 85155c39d3a6253e2ba865eafab30edcf2ff02f61efc9d21ba3c68f14a2a9d42
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
